High frequency of neutralizing antibodies to type I Interferon in HIV-1 patients hospitalized for COVID-19

High frequency of neutralizing antibodies to type I Interferon in HIV-1 patients hospitalized for COVID-19

Copyright © 2022 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 241(2022) vom: 05. Aug., Seite 109068
1. Verfasser: Scordio, Mirko (VerfasserIn)
Weitere Verfasser: Frasca, Federica, Santinelli, Letizia, Sorrentino, Leonardo, Pierangeli, Alessandra, Turriziani, Ombretta, Mastroianni, Claudio M, Antonelli, Guido, Viscidi, Raphael P, d'Ettorre, Gabriella, Scagnolari, Carolina
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2022
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Letter Research Support, Non-U.S. Gov't HIV-1 HIV-1 and SARS-CoV-2 co-infection ISGs Interferon Neutralizing antibodies SARS-CoV-2 Antibodies, Neutralizing Antibodies, Viral mehr... Interferon Type I Interferon-alpha
Beschreibung
Zusammenfassung:Copyright © 2022 Elsevier Inc. All rights reserved.
The presence of anti-IFN neutralizing antibodies (NAB) has been reported in critically ill COVID-19 patients. We found that 87.5% (7/8) of HIV-1 patients co-infected with SARS-CoV-2 had serum anti-IFN-I NAB against IFN-α subtypes, IFN-β and/or IFN-ω. Anti-IFN-I NAB were also detected in oropharyngeal samples. Patients with NAB were males, and those with high serum anti-IFN-α/ω NAB titer had severe illness and exhibited reduction in the expression of IFN-stimulated genes. Thus, high titer of anti-IFN-α/ω NAB may contribute to the greater severity of COVID-19 in HIV-1 infected patients
Beschreibung:Date Completed 09.08.2022
Date Revised 09.09.2024
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2022.109068